Maria Filomena Caiaffa

1.8k total citations
48 papers, 875 citations indexed

About

Maria Filomena Caiaffa is a scholar working on Immunology and Allergy, Physiology and Dermatology. According to data from OpenAlex, Maria Filomena Caiaffa has authored 48 papers receiving a total of 875 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology and Allergy, 17 papers in Physiology and 14 papers in Dermatology. Recurrent topics in Maria Filomena Caiaffa's work include Allergic Rhinitis and Sensitization (21 papers), Asthma and respiratory diseases (16 papers) and Urticaria and Related Conditions (10 papers). Maria Filomena Caiaffa is often cited by papers focused on Allergic Rhinitis and Sensitization (21 papers), Asthma and respiratory diseases (16 papers) and Urticaria and Related Conditions (10 papers). Maria Filomena Caiaffa collaborates with scholars based in Italy, Sweden and United States. Maria Filomena Caiaffa's co-authors include Luigi Macchia, Alfredo Tursi, Francesca Fornelli, Danilo Di Bona, Marcello Albanesi, Jesper Z. Haeggström, Giacomino Randazzo, Antonio Moretti, Antonio Logrieco and Alberto Ritieni and has published in prestigious journals such as Applied and Environmental Microbiology, Biochemical and Biophysical Research Communications and Frontiers in Immunology.

In The Last Decade

Maria Filomena Caiaffa

46 papers receiving 852 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maria Filomena Caiaffa Italy 17 403 301 286 163 101 48 875
S Yoshida Japan 13 265 0.7× 97 0.3× 120 0.4× 69 0.4× 27 0.3× 26 682
S J Newsholme United States 13 236 0.6× 75 0.2× 112 0.4× 60 0.4× 26 0.3× 25 557
Yasuo Yui Japan 14 319 0.8× 462 1.5× 70 0.2× 25 0.2× 37 0.4× 25 772
Linda L. Walker United States 16 210 0.5× 74 0.2× 68 0.2× 138 0.8× 25 0.2× 24 958
R.J. Dearman United Kingdom 15 182 0.5× 203 0.7× 97 0.3× 34 0.2× 20 0.2× 26 864
R.A. Merendino Italy 12 231 0.6× 235 0.8× 57 0.2× 46 0.3× 12 0.1× 32 617
A. Prouvost-Danon France 15 136 0.3× 218 0.7× 31 0.1× 47 0.3× 22 0.2× 43 660
Esther de Jong Netherlands 12 135 0.3× 108 0.4× 15 0.1× 35 0.2× 16 0.2× 19 777
C.H. Bridts Belgium 13 83 0.2× 383 1.3× 36 0.1× 13 0.1× 58 0.6× 21 585
Lai‐Chen Tsai Taiwan 15 145 0.4× 215 0.7× 30 0.1× 16 0.1× 10 0.1× 34 534

Countries citing papers authored by Maria Filomena Caiaffa

Since Specialization
Citations

This map shows the geographic impact of Maria Filomena Caiaffa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Filomena Caiaffa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Filomena Caiaffa more than expected).

Fields of papers citing papers by Maria Filomena Caiaffa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Filomena Caiaffa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Filomena Caiaffa. The network helps show where Maria Filomena Caiaffa may publish in the future.

Co-authorship network of co-authors of Maria Filomena Caiaffa

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Filomena Caiaffa. A scholar is included among the top collaborators of Maria Filomena Caiaffa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Filomena Caiaffa. Maria Filomena Caiaffa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Carpagnano, Giovanna Elisiana, Andrea Portacci, Santi Nolasco, et al.. (2024). Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission. Frontiers in Immunology. 15. 1343362–1343362. 18 indexed citations
2.
Portacci, Andrea, Raffaele Campisi, Enrico Buonamico, et al.. (2023). Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. ERJ Open Research. 9(5). 419–2023. 11 indexed citations
3.
Scioscia, Giulia, Pasquale Tondo, Santi Nolasco, et al.. (2023). Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience. Journal of Clinical Medicine. 12(13). 4362–4362. 4 indexed citations
4.
Nolasco, Santi, Andrea Portacci, Raffaele Campisi, et al.. (2023). Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study. Frontiers in Immunology. 14. 1204444–1204444. 24 indexed citations
5.
Giangaspero, Annunziata, et al.. (2022). When there is no communication between urban planners and public health operators: urban Dermanyssus gallinae infestations in humans.. PubMed. 79(2). 62–69. 1 indexed citations
6.
Rollo, Valentina, Albina Tummolo, Patrizia Suppressa, et al.. (2022). Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS). Orphanet Journal of Rare Diseases. 17(1). 402–402. 5 indexed citations
7.
Chaoul, Nada, María Pía Rossi, Marcello Albanesi, et al.. (2021). Sustained drug-related reaction with eosinophilia and systemic symptoms (DRESS) triggered by low molecular weight heparins in COVID-19: management and precision diagnosis. Advances in Dermatology and Allergology. 39(4). 816–818. 2 indexed citations
8.
Bona, Danilo Di, Eustachio Nettis, Massimo Bilancia, et al.. (2021). Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study. The Journal of Allergy and Clinical Immunology In Practice. 9(6). 2482–2485.e2. 4 indexed citations
9.
Nolasco, Santi, Claudia Crimi, Corrado Pelaia, et al.. (2021). Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study. The Journal of Allergy and Clinical Immunology In Practice. 9(12). 4371–4380.e4. 49 indexed citations
10.
Albanesi, Marcello, Nada Chaoul, Danilo Di Bona, et al.. (2020). Safety of measles, mumps, and rubella vaccine in egg allergy: in vivo and in vitro management. Clinical and Molecular Allergy. 18(1). 21–21. 4 indexed citations
11.
Bona, Danilo Di, et al.. (2020). Benralizumab improves patient reported outcomes and functional parameters in difficult-to-treat patients with severe asthma: Data from a real-life cohort. Pulmonary Pharmacology & Therapeutics. 64. 101974–101974. 5 indexed citations
12.
Chaoul, Nada, Marcello Albanesi, María Pía Rossi, et al.. (2019). Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects. International Archives of Allergy and Immunology. 179(1). 37–42. 2 indexed citations
13.
Albanesi, Marcello, et al.. (2018). A 13-year real-life study on efficacy, safety and biological effects of Vespula venom immunotherapy. Clinical and Molecular Allergy. 16(1). 2–2. 11 indexed citations
14.
Bona, Danilo Di, et al.. (2017). Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respiratory Medicine. 130. 55–60. 65 indexed citations
15.
Giacomo, Mariangela Di, et al.. (2015). The lymphocyte proliferation test (LPT) in the diagnosis of critical cases of delayed drug allergy.. CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro). 335.
16.
Damiani, Elisabetta, et al.. (2014). Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases. Allergy. 580. 2 indexed citations
17.
Novelli, Federica, Manuela Latorre, Maria Filomena Caiaffa, et al.. (2014). Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy. Pulmonary Pharmacology & Therapeutics. 31. 123–129. 37 indexed citations
18.
Fornelli, Francesca, et al.. (2003). Cytotoxic effects of the mycotoxin beauvericin to human cell lines of myeloid origin. Pharmacological Research. 49(1). 73–77. 52 indexed citations
19.
Paola, Roberto Di, Alfredo Tursi, Joseph H. Butterfield, et al.. (1999). 5-Lipoxygenase Upregulation by Dexamethasone in Human Mast Cells. Biochemical and Biophysical Research Communications. 265(3). 617–624. 25 indexed citations
20.
Macchia, Luigi, Roberto Di Paola, Luigi Mario Chiechi, et al.. (1997). Expression of Prostaglandin Endoperoxide H Synthase 1 and 2 in Human Placenta at Term. Biochemical and Biophysical Research Communications. 233(2). 496–501. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S Yoshida Breakdown of academic impact, for papers by S J Newsholme Breakdown of academic impact, for papers by Yasuo Yui Breakdown of academic impact, for papers by Linda L. Walker Breakdown of academic impact, for papers by R.J. Dearman Breakdown of academic impact, for papers by R.A. Merendino Breakdown of academic impact, for papers by A. Prouvost-Danon Breakdown of academic impact, for papers by Esther de Jong Breakdown of academic impact, for papers by C.H. Bridts Breakdown of academic impact, for papers by Lai‐Chen Tsai
Rankless by CCL
2026